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induce immune tolerance may also be required to mini-
mize rejection.Figure 1. Recovery of T cell subsets after matched and mismatched ASCT353
Reconstitution of Lymphocyte Subsets and Outcomes
After Matched and Mismatched Hematopoietic Stem-Cell
Transplantation
Antonio di Stasi 1, Michelle Poon 2, Amir Hamdi 2, Hila Shaim 3,
Susan Xie 3, Denai Milton 3, Roland Bassett Jr. 4,
Gabriela Rondon 2, Elizabeth J. Shpall 5, Laurence J.N. Cooper 6,
Dean A. Lee 7, Katayoun Rezvani 8, Richard E. Champlin 5,
Stefan O. Ciurea 2. 1 SCT, MDACC, Houston, TX; 2 Stem Cell
Transplantation and Cellular Therapy, The University of Texas
MD Anderson Cancer Center, Houston, TX; 3MDACC;
4Department of Biostatistics, The University of Texas MD
Anderson Cancer Center, Houston, TX; 5 UT MD Anderson
Cancer Center, Houston, TX; 6 Pediatrics, UT MDACC, Houston,
TX; 7 Pediatrics, University of Texas MD Anderson Cancer
Center, Houston, TX; 8 Stem Cell Transplantation & Cellular
Therapy, MD Anderson Cancer Center, Houston, TX
Allogeneic stem-cell transplantation (ASCT) is curative for
many malignant and nonmalignant hematological disorders.
We aimed to study reconstitution of lymphocyte subsets
after matched and mismatched transplantation.
Lymphocyte subsets were evaluated by ﬂow cytometry at
1,3,6 and 12 months (mo) post-ASCT. Lymphocyte recovery
was determined using means at each time point and group
differences assessed using analysis of variance.Time-to-
event outcome were estimated by Kaplan-Meier survival
curves and the log-rank test was used to evaluate differences
between groups. 100 patients (pts) were included in the
study: 25 received a matched sibling (MSD), 20 pts
a matched unrelated donor ASCT 10/10 (MUD), 18 pts a 9/10
MUD, 9 pts a T cell depleted haploidentical (TCD haplo), and
28 a T cell replete haploidentical transplant (TCR haplo). 53
pts received bone marrow and 47 peripheral blood stem
cells. Most patients were treated for acute leukemia (AML 41,
ALL 23), 16 MDS, 6 CML, 4 CLL, 5 lymphoma. Median age was
43 years (range: 20-71). Median follow-up was 13.6 mo. 60
pts were alive and disease-free at last follow-up and 28 pts
died 75% of relapse. Non-relapse mortality (NRM) was 6% for
the entire cohort.
Overall, alive pts (vs. who died) had higher mean CD3
(615 vs. 349, P ¼ .03 on day 90), CD8 (427 vs. 187, P ¼ .03 on
day 90), CD4 (391 vs. 54, P¼ .01, on day 365), and lowermean
CD56 cells (178 vs 300, P¼ .01, on day 30) post ASCT. Pts who
progressed (vs. did not), had lower 1 year mean CD4 (123 vs.
394, P ¼ .02), lower mean CD3 (359 vs. 1147,P ¼ .06), with no
differences in CD8, NK, and CD45RA cells. NRM was associ-
ated with higher mean NK counts at 6 months (499 vs. 188,
P ¼ .01) and with lower mean CD3 at day 90 (184 vs. 557,
P ¼ .07). T-cell recovery occurred most rapidly in MSD
transplants (Figure1), and interestingly, higher CD4CD25 cell
numbers recovered early and most rapidly in the MSD
transplants, which may partly explain a lower incidence of
GVHD in this group. Overall, TCR haplos had a similar pattern
of T-cell recovery and outcomes as 10/10 MUDs (Figure1). No
signiﬁcant differences in T cell subsets found between these
two groups for CD3, CD4, CD8, CD45RA and CD4CD25 at any
time-point. TCD haplos had most impaired T-cell reconsti-
tution and outcomes (Fig. 1), characterized by early NK cell
and delayed CD3, CD4, CD8 recovery. Interestingly, pts
surviving 6-9 months post-transplant recovered CD3, C4,
CD8 cells; however, naïve T-cell recovery was impaired for
more than >1 year post-transplant, suggesting that T cellrecovery comes predominantly from the memory T cell
compartment.
In conclusion, recovery of lymphocyte subsets may
vary widely with the type of transplant, may correlate
with outcomes, and should be further explored post-
transplant.354
Immune Modulation of Antibody Responses Induced
Through Allogeneic Cell Transplantation
Raimon Duran-Struuck 1,2, Mihail Climov 1,2, Ashley Gusha 1,
Edward Harrington 1, Abraham J. Matar 1,3,
Rebecca L. Crepeau 1, Thomas R. Spitzer 4,5, David H. Sachs 1,2,
Christene A. Huang 1,2. 1 Transplantation Biology Research
Center, Massachusetts General Hospital, Boston, MA;
2Department of Surgery, Harvard Medical School, Boston, MA;
3 University of Central Florida College of Medicine, Orlando, FL;
4 Bone Marrow Transplantation Unit, Massachusetts General
Hospital, Boston, MA; 5Department of Medicine, Harvard
Medical School, Boston, MA
Combined renal and hematopoietic cell transplantation
(HCT) protocols have successfully induced allograft tolerance
despite loss of chimerism in patients; however, the mecha-
nism remains unclear. Using a miniature swine model with
demonstrated clinical relevance, we assessed immune
responses following HCT in ten recipients that lost chime-
rism. All animals received 30 days of cyclosporine (CyA) with
taper until day 45; low-dose total body irradiation (100cGy
TBI) and T cell depletion using a CD3 immunotoxin (pCD3-
IT). Six animals received mobilized donor cells and 4 animals
received unmobilized cells. Control animals received allo-
geneic cells without any immunosuppression. Cellular
responses were assessed bymixed lymphocyte reactivity and
cell mediated lympholysis assays. Donor speciﬁc antibody
was assessed by ﬂow cytometry and complement mediated
cytotoxicity assays.
Following loss of chimerism, anti-donor cellular prolifer-
ative and cytotoxic responses returned without alloantibody.
Alloantibody responses were not induced even after a second
exposure to donor cells intravenously without immunosup-
pression (n¼10) or following donor skin graft rejection
(n¼3). Attempts to further immunize some of these animals
(n¼6) with multiple subcutaneous injections of donor cells
with or without complete Freund's adjuvant also failed to
induce donor speciﬁc antibody. In contrast, control animals
exposed to donor cells without conditioning had sustained
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following either intravenous (n¼2) or subcutaneous (n¼2)
injection of cells as well as following skin graft rejection.
These results suggest that exposure to donor cells
following reduced intensity conditioning can result in
robust immune modulation of antibody responses to
allogeneic cells. B cell unresponsiveness is stable and does
not depend on persistence of unresponsiveness at the T
cell level or the persistence of donor cells. We speculate
that this mechanism of immune modulation of B cell
responses by allogeneic cells may play an important role
in facilitating induction of transplantation tolerance
through HCT.355
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Graft-versus-host disease (GVHD) remains a frequent
complication of hematopoietic cell transplantation (HCT)
with skin being a principal target organ. Murine models
have provided some insight into the mechanisms of this
complex disease process. However, mouse skin differs
from human skin, and results of studies in rodents may
not translate well to the clinic. The pig is a well-
recognized animal model for preclinical studies of skin
including dermal toxicology, transdermal drug delivery
and wound healing. Unlike skin of rodents, dogs or non-
human primates, porcine skin is similar to human skin
in terms of structure of epidermal rete ridges, hair
follicle structure and density, and presence of sweat
glands and subcutaneous fat. Because of the similarities
of pig skin to human skin and availability of swine with
deﬁned MHC genes, MGH miniature swine provide
a valuable pre-clinical model of HCT for studies of graft-
versus-host disease. HCT between MHC matched or
mismatched animals can be performed to mimic clinical
HCT scenarios with outcomes that closely resemble
those observed in human HCT recipients. With myeloa-
blative conditioning, HCT across MHC barriers is most
often fatal, with animals developing severe grade III-IV
GVHD involving the gastrointestinal tract (GI), liver and
skin. We have developed a comprehensive GVHD scoring
system for pigs which parallels that used clinically (see
chart). Unlike rodent models, miniature swine provide
an opportunity to perform extended longitudinal
studies, since multiple tissue biopsies can be taken
without the need to sacriﬁce the animal. Given the
similarities of GVHD in pigs and humans, we hope that
the utilization of the pig and scoring system facilitates
scientiﬁc discourse between the laboratory and the
clinic. We anticipate that results of swine studies will be
applicable to the development of new strategies to
improve GVHD identiﬁcation and treatment in clinical
HCT scenarios.356
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Background: Allogeneic HSCT from an HLA-matched sibling
donor is the recommended treatment approach in patients
with SAA, at least up to the age of 40 years. Cyclophospha-
mide (Cy)-ATG is the standard, non-myeloablative condi-
tioning regimen, while BM stem cells are the preferred
source of engraftment.
Aims:We have already published our data regarding the use
of PBSCs in patients with SAA conditioned with the Fludar-
abine (Flu)-Cy regimen (EBMT, Czech Republic 2005, Poster
Abst # 782 / CBMTG, Montreal 2008, oral Abst # 02). In this
single arm prospective study, we investigated the use of
FlueCy to allograft SAA patients >20 years old, using PBSCs.
Patients & methods: In the time period between May 2003
and December 2009, 53 heavily pre-transfused SAA patients
received allogeneic HLA- identical sibling PBSCs at the BMT
unit of Nasser institute, Cairo, Egypt. All patients were above
the age of 20 years (range 21- 41 years, mean 27 years). The
regimen consisted of Flu at a total dose ranging from 75mg-
120mg/ m2, and a total Cy dose of 200mg/kg. Our primary
endpoints were incidence and severity of chronic GVHD, as
well as DFS & OS. Cyclosporine & Methotrexate were used for
GVHD prophylaxis.
